Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 9/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.38 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.38 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.38 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.38 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.38 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.38 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.38 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25748318 | 0.79 | ACHE (0.43) | RHEBP2RX7BRD4IMPDH2TUBB4A | |
| SCHEMBL31513824 | 0.79 | MEN1 (0.52) | RHEBALDH1A1BRD4TUBB4ATUBB | |
| SCHEMBL5925752 | 0.79 | MEN1 (0.52) | RHEBALDH1A1BRD4TUBB4ATUBB | |
| SCHEMBL29507025 | 0.78 | RHEB (0.42) | RHEBAHRBRD4IMPDH2TUBB4A | |
| SCHEMBL1960019 | 0.78 | TRPA1 (0.44) | RHEBP2RX7AHRBRD4IMPDH2 | |
| SCHEMBL30483768 | 0.78 | TRPA1 (0.44) | RHEBP2RX7AHRBRD4IMPDH2 | |
| SCHEMBL1163434 | 0.78 | RHEB (0.42) | RHEBAHRBRD4IMPDH2TUBB4A | |
| SCHEMBL20536439 | 0.77 | RHEB (1.00) | RHEBALDH1A1CMA1AHR | |
| SCHEMBL30396837 | 0.77 | RHEB (0.58) | RHEBALDH1A1CMA1AHR | |
| SCHEMBL20536293 | 0.75 | RHEB (1.00) | RHEBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
| WO-2022133588-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-06-30 | — | — | WO | disclosed |
| US-20220204476-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-06-30 | — | — | US | disclosed |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| US-9434724-B2 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434724-B2 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | ALPHARMAGEN, LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | ALPHARMAGEN, LLC | 2016-01-14 | — | — | US | disclosed |
| WO-2016007630-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7 -NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN, LLC (US) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204476-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | SARS1, NSUN3, GTF3C4 | RHEB 1274/4885ALDH1A1 2958/4885P2RX7 3773/4885 |
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | RHEB 468/4885ALDH1A1 4135/4885P2RX7 1033/4885 |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | CHRNA7, CHRNA2, CHRNA5 | RHEB 2671/4885ALDH1A1 1525/4885P2RX7 63/4885 |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNA7, CHRNA2, CHRNA6 | RHEB 2940/4885ALDH1A1 1497/4885P2RX7 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.